Regenerative Medicine Sector ARMs Itself With New Advocacy Group
This article was originally published in The Gray Sheet
Executive Summary
Companies and researchers developing cell-based and tissue engineering therapies have formed a lobbying group to improve the federal policy environment surrounding their efforts